ImmuCell (NASDAQ:ICCC) released its earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. ImmuCell had a net margin of 0.60% and a return on equity of 0.28%.
Shares of ImmuCell (NASDAQ:ICCC) traded down $0.04 on Friday, reaching $7.02. 7,191 shares of the company’s stock were exchanged, compared to its average volume of 9,129. The company has a market capitalization of $38.61, a PE ratio of 706.71 and a beta of 1.03. The company has a current ratio of 1.75, a quick ratio of 0.99 and a debt-to-equity ratio of 0.27. ImmuCell has a 1 year low of $5.00 and a 1 year high of $9.25.
Separately, ValuEngine upgraded shares of ImmuCell from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.
COPYRIGHT VIOLATION WARNING: “ImmuCell (ICCC) Posts Quarterly Earnings Results” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/09/immucell-iccc-posts-quarterly-earnings-results-2.html.
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.